An online-first Nature Communications paper defines a PRMT5-dependent mechanism that sustains replication-coupled histone production. The result is relevant to oncology programs inhibiting PRMT5, but it also underscores potential normal-tissue toxicity from disrupting a cell-essential…
Iambic Therapeutics priced its initial public offering of 9,375,000 common shares at $16 per share for $150 million of expected gross proceeds before underwriting discounts and expenses. Trading under IAM began on Nasdaq on…
InnoCare Pharma entered a research collaboration and license agreement with Eli Lilly covering compounds against as many as five undisclosed targets. InnoCare may receive up to $100 million in upfront and near-term payments, approximately…
Asieris disclosed that Chief Scientific Officer Ningshu Liu resigned for personal reasons and will hold no continuing role. The filing was dated September 19, roughly eight months after her appointment to lead early discovery…
Envisagenics and Boehringer Ingelheim entered a multi year research and option agreement to discover and validate tumor specific targets derived from alternative RNA splicing. Boehringer may develop selected targets using antibody drug conjugates, T…
Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President and Worldwide Chairman, Innovative Medicine. Tom Cavanaugh, currently Company Group Chairman for North America, Innovative Medicine, will succeed her and join…
BioNTech’s Supervisory Board has appointed Guido Oelkers to the Management Board as Chief Executive Officer, effective no later than February 1, 2027. He succeeds co-founder Ugur Sahin, who will support the onboarding transition and…
Tempus AI agreed to acquire Personalis for $16.25 per share, representing an enterprise value of approximately $1.5 billion net of Tempus’ existing ownership. The deal integrates Personalis’ tumor-informed minimal residual disease testing with Tempus’…
Bristol Myers Squibb is expanding its NVIDIA collaboration with a second DGX SuperPOD built on eight Vera Rubin NVL72 systems. The infrastructure is intended to make large-scale AI broadly available across BMS research, from…
Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients.
